Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 25, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 11,582 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on October 24, 2005, and was notified to the Company on October 25, 2005.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Investor Verification Points
- Verify the impact of the 11,582 share transfer on the total outstanding share count.
- Confirm the specific identities of the participants in the SmithKline Beecham Employee Share Option Plan 1991 who received the shares.
- Note that Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.